Chien-Fu Hung Selected Research

DNA Vaccines

9/2021	Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine.
1/2021	Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
5/2019	Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines.
12/2018	Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination.
1/2018	Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice.
1/2018	Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control.
1/2018	Intramuscular vaccination targeting mucosal tumor draining lymph node enhances integrins-mediated CD8+ T cell infiltration to control mucosal tumor growth.
1/2018	Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.
12/2017	Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7.
1/2017	Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chien-Fu Hung Research Topics

Disease

167	Neoplasms (Cancer) 05/2022 - 03/2002
25	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2007
25	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2021 - 01/2007
22	Infections 12/2021 - 03/2003
20	Papillomavirus Infections 01/2021 - 01/2003
9	Communicable Diseases (Infectious Diseases) 01/2022 - 02/2003
9	Vaccinia 01/2021 - 11/2002
5	Hepatocellular Carcinoma (Hepatoma) 10/2018 - 03/2011
5	Carcinogenesis 12/2013 - 07/2007
4	Tuberculosis (Tuberculoses) 10/2021 - 11/2016
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 07/2017
3	Leiomyoma (Uterine Fibroids) 03/2021 - 10/2003
3	Melanoma (Melanoma, Malignant) 01/2021 - 02/2012
3	Condylomata Acuminata (Genital Wart) 01/2021 - 11/2014
3	Uterine Cervical Dysplasia 01/2021 - 02/2016
3	Ascites 01/2020 - 07/2007
3	Virus Diseases (Viral Diseases) 03/2010 - 09/2003
2	Squamous Cell Carcinoma of Head and Neck 04/2022 - 01/2022
2	Carcinoma (Carcinomatosis) 01/2022 - 01/2003
2	Head and Neck Neoplasms (Head and Neck Cancer) 09/2021 - 12/2012
2	Multiple Myeloma 01/2021 - 01/2015
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 02/2007
2	Ovarian Epithelial Carcinoma 01/2018 - 12/2017
2	Skin Neoplasms (Skin Cancer) 01/2018 - 07/2013
2	Recurrent respiratory papillomatosis 01/2018 - 11/2010
2	Papilloma (Papillomatosis) 01/2018 - 01/2017
2	Inflammation (Inflammations) 09/2016 - 03/2015
2	Hyperthermia 09/2015 - 01/2013
2	Pancreatitis 03/2015 - 01/2009
2	Necrosis 01/2014 - 03/2010

Drug/Important Bio-Agent (IBA)

67	AntigensIBA 01/2022 - 03/2002
55	DNA VaccinesIBA 09/2021 - 03/2002
53	VaccinesIBA 01/2022 - 01/2003
47	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 03/2002
37	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2002
24	Therapeutic UsesIBA 01/2018 - 04/2007
23	Papillomavirus Vaccines (HPV Vaccines)IBA 09/2021 - 01/2007
19	Peptides (Polypeptides)IBA 01/2022 - 03/2003
16	A-Form DNA (A-DNA)IBA 01/2021 - 05/2004
15	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 11/2002
12	CalreticulinIBA 01/2020 - 08/2004
10	Oncogene Proteins (Oncogene Protein)IBA 04/2021 - 07/2006
10	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 05/2008
9	Pharmaceutical PreparationsIBA 01/2022 - 01/2007
9	LuciferasesIBA 01/2020 - 07/2007
8	EpitopesIBA 01/2022 - 03/2003
5	LigandsIBA 01/2022 - 04/2009
5	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2021 - 01/2015
5	MesothelinIBA 01/2018 - 01/2007
4	HLA-A2 Antigen (HLA A2 Antigen)IBA 04/2022 - 01/2007
4	Immune Checkpoint InhibitorsIBA 04/2021 - 12/2017
4	Interleukin-2 (IL2)IBA 01/2021 - 12/2007
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 07/2010
4	Bortezomib (Velcade)FDA Link 01/2021 - 08/2008
4	UbiquitinIBA 01/2021 - 10/2016
4	Paclitaxel (Taxol)FDA LinkGeneric 07/2014 - 01/2013
3	TransposasesIBA 09/2021 - 01/2018
3	Imiquimod (Aldara)FDA LinkGeneric 01/2021 - 04/2010
3	Annexin A5IBA 01/2021 - 09/2016
3	PiperidonesIBA 01/2021 - 10/2016
3	RA190IBA 01/2021 - 10/2016
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2019
3	Monoclonal AntibodiesIBA 01/2018 - 08/2008
3	AntibodiesIBA 01/2018 - 08/2008
3	CytokinesIBA 09/2016 - 07/2011
3	Neutralizing AntibodiesIBA 01/2015 - 01/2007
3	Tumor Viral Antigens (Large T Antigen)IBA 07/2013 - 10/2008
3	Poly I-CIBA 08/2011 - 07/2004
3	OvalbuminIBA 07/2011 - 07/2009
3	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 05/2009 - 10/2007
3	Small Interfering RNA (siRNA)IBA 08/2008 - 01/2005
2	Interferon Type IIBA 01/2022 - 12/2017
2	Fumarate Hydratase (Fumarase)IBA 03/2021 - 02/2020
2	Capsid Proteins (Capsid Protein)IBA 01/2021 - 01/2007
2	InterleukinsIBA 01/2021 - 01/2013
2	Isoniazid (Ftivazide)FDA LinkGeneric 01/2020 - 11/2016
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 11/2016
2	Sorafenib (BAY 43-9006)FDA Link 10/2018 - 01/2018
2	Immunoglobulin G (IgG)IBA 01/2018 - 02/2013
2	18 16 11 Types 6 Human Papillomavirus Recombinant Vaccine Quadrivalent (Gardasil)FDA Link 01/2018 - 12/2007
2	ApigeninIBA 07/2017 - 05/2009
2	Interferon-gamma (Interferon, gamma)IBA 07/2017 - 03/2002
2	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 03/2016 - 08/2008
2	Histone Deacetylase InhibitorsIBA 01/2015 - 10/2013
2	PlatinumIBA 05/2014 - 01/2013
2	Fluorouracil (Carac)FDA LinkGeneric 03/2014 - 03/2011
2	N-formylmethionylphenylalanine (FMP)IBA 03/2014 - 03/2011
2	Mitoxantrone (Novantrone)FDA LinkGeneric 03/2014 - 03/2011
2	AutoantigensIBA 01/2014 - 02/2013
2	Histocompatibility Antigens Class IIBA 10/2013 - 07/2004
2	Galactosylceramides (Galactocerebrosides)IBA 01/2013 - 10/2010

Therapy/Procedure

53	Immunotherapy 01/2022 - 03/2002
34	Therapeutics 01/2022 - 10/2003
20	Drug Therapy (Chemotherapy) 01/2021 - 01/2007
9	Investigational Therapies (Experimental Therapy) 07/2013 - 10/2007
7	Radiotherapy 01/2018 - 05/2009
4	Intraperitoneal Injections 05/2019 - 07/2007
2	Hysterectomy 03/2021 - 02/2020
2	Lasers (Laser) 09/2015 - 04/2009
2	Combination Drug Therapy (Combination Chemotherapy) 03/2014 - 03/2011